Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Overview: Myriad is a biopharmaceutical company operating two primary segments: Research (gene discovery, sequencing, and therapeutic product development) and Predictive Medicine (testing for disease predisposition). The company has not yet attained profitability and relies on collaborative agreements and predictive medicine sales for revenue.
Key Financial Metrics
| Metric (in thousands) | Q3 2002 | Q3 2001 |
|---|---|---|
| Total Revenues | $15,511 | $13,190 |
| Net Loss | $(5,316) | $(1,185) |
| Operating Loss | $(6,072) | $(2,967) |
| Cash and Cash Equivalents (End of Period) | $48,519 | $47,358 |
| Total Cash & Marketable Securities | $103,661 | $136,251 |
| Net Cash Used in Operating Activities | $(18,059) | $(9,822) |
| Accumulated Deficit | $(79,142) | Not Provided |
Segment Performance (Q3 2002):
- Research Revenue: $7.647 million (includes $0.632 million related party revenue).
- Predictive Medicine Revenue: $7.864 million.
- Predictive Medicine Cost of Revenue: $2.921 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 17.6% year-over-year, driven primarily by a 43% increase in Predictive Medicine revenue ($2.3 million increase). Research revenue declined 9% due to a strategic shift toward internal drug development.
- Expense Increases:
- R&D Expenses: Increased 33% to $10.9 million, attributed to clinical trials for prostate cancer and Alzheimer's disease.
- Selling, General & Administrative (SG&A): Increased 37% to $7.7 million, driven by an expanded sales force and direct-to-consumer marketing campaigns.
- Profitability: Net loss widened significantly from $1.2 million to $5.3 million due to higher operating costs outpacing revenue growth.
- Liquidity: Cash and marketable securities decreased by approximately $32.6 million (24%) compared to the prior year, reflecting capital expenditures and increased operational spending. Interest income dropped 56% to $0.8 million due to lower cash balances and interest rates.
Outlook, Risks, and Management Commentary
Management Outlook:
- Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and predictive medicine product launches.
- The company believes existing capital resources are sufficient to fund operations for at least the next two years.
- Future capital requirements will depend on the progress of clinical activities, patent enforcement costs, and the commercialization of new discoveries.
Key Risks and Contingencies:
- Regulatory & Clinical Risk: Delays in clinical trials or failure to secure regulatory approval for drug candidates (e.g., Flurizan for prostate cancer/Alzheimer's).
- Collaboration Dependence: Revenue relies heavily on payments from pharmaceutical partners; failure to secure new collaborations could impact funding.
- Market Competition: Risks associated with competing technologies and the ability to protect proprietary patents.
- Legal: No material legal proceedings were reported as of the filing date.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $18.1 million quarterly operating cash burn against the $103.7 million total liquid asset base.
- Clinical Trial Progress: Monitor the status of the Flurizan (MPC-7869) clinical trials for prostate cancer and the IND application for Alzheimer's disease.
- Revenue Mix: Assess the sustainability of the 43% growth in predictive medicine sales versus the decline in research collaboration revenue.
- Capital Needs: Review the $250 million shelf registration statement (Form S-3) to understand potential dilution if additional financing is required sooner than the projected two-year runway.
- Related Party Transactions: Note the $632,000 revenue from Myriad Proteomics, Inc. (49% owned) and the implications of this joint venture on future revenue streams.